Reasons for Selecting Vietnam: Ability of Producing a Stable Supply of Japanese Quality
Nipro Pharma selected Hai Phong Vietnam, as the location for its first overseas production. This was because diligent people and reliable infrastructure would be available in Vietnam to achieve Japanese quality, and because the geopolitical conditions of Vietnam would guarantee stable supply systems. Toward economic integration of ASEAN countries, the development of surrounding markets in Asia is also expected.
Stable supply of high-quality pharmaceutical products
A reliable workforce is indispensable to achieve Japanese quality. Vietnamese people are diligent and are friendly to the Japanese. Economic exchange between Japan and Vietnam is also vibrant, and local underlying industries are expected to develop with support from Japanese companies, which will lead to further quality enhancement and cost reduction in Vietnam.
Toward economic integration of ASEAN countries, the development of surrounding markets is also expected
Among developing countries, dramatic economic growth is expected in Vietnam. Looking toward economic integration of ASEAN countries slated for 2015, the new company is expected to function as an ideal base for developing markets, not only in Vietnam, but also in other rapidly growing markets of surrounding countries in Asia.
Location and infrastructure of the highest class in Vietnam
NIPRO Pharma Vietnam Co., Ltd. is located in the VSIP industrial complex in Hai Phong the third largest city in Vietnam. Here, we have infrastructure providing water and electricity of the highest class in Vietnam. A highway will be completed in 2015 providing access from Hai Phong to Hanoi, the capital of Vietnam, in only one hour by car. Direct flights between Hai Phong and Japan will also start in 2015, achieving an access in as little as five hours.
Production lines conforming with the U.S., EU, and Japan GMP requirements and with PIC/S GMP
The site of NIPRO Pharma Vietnam Co., Ltd. has an area of approximately 150,000 square meters, equivalent to 18 football fields. An ampoule plant will start operation in April 2015, in conformity with the U.S., EU, and Japan GMP requirements and with PIC/S GMP. A vial solution and freeze-dried product plant will also start operation in July 2016. The production lines will be further expanded to enable the production of orally administered drugs and external preparations, in accordance with the needs of pharmaceutical companies.
Back to Industrial News Main Page
Singapore Industrial Automation Association